Johnson & Johnson

• JNJ Stock Price 24h change: +0.59%. From 218.01 USD to 219.30 USD. The stock rose slightly after investors digested a "beat-and-raise" Q4 report, with 2026 guidance surpassing Wall Street estimates despite ongoing talc litigation concerns and a drug-pricing deal with the administration.
• From a technical perspective, JNJ exhibits a "Strong Buy" signal across multiple timeframes. The stock is trading above its 50-day ($207.86) and 200-day ($188.48) moving averages, suggesting a robust uptrend; an RSI of 57.14 indicates steady momentum without being overbought.
• Johnson & Johnson reported Q4 revenue of $24.6 billion, up 9.1% YOY, and issued a bullish 2026 sales forecast of up to $100.5 billion, signaling confidence in its oncology and MedTech pipeline.
• The company reached a strategic agreement with the U.S. administration to lower certain drug prices in exchange for tariff exemptions, an impact J&J claims is already "digested" in its positive 2026 outlook.
• J&J announced the $3.05 billion acquisition of Halda Therapeutics to bolster its cancer treatment portfolio, alongside plans to spin off its orthopedics business, DePuy Synthes, within 18-24 months.
• The U.S. House Committee on the Budget held hearings on January 21, 2026, focused on skyrocketing healthcare costs, while Congress reached a deal to boost HHS spending and reform Pharmacy Benefit Manager (PBM) transparency.
• The FTC and Evernorth are reportedly nearing a settlement regarding insulin price-fixing allegations, reflecting a broader regulatory crackdown on drug-industry middlemen to lower consumer costs.

• JNJ Stock Price 24h change: -0.09%. From 218.21 USD to 218.01 USD. The price dipped slightly as legal concerns regarding talc litigation offset a strong 2026 sales and profit forecast that exceeded analyst expectations.
• From a technical perspective, JNJ presents a "Strong Buy" configuration: the 50-day moving average ($215.47) and 200-day moving average ($209.47) are both trending below the current price, indicating a robust long-term bullish trend. The 14-day RSI stands at 56.2, suggesting the stock remains in a healthy uptrend without being overbought.
• J&J reported Q4 2025 revenue of $24.56 billion, beating estimates driven by a 27% surge in Darzalex sales and raised its 2026 operational sales guidance to $99.5B–$100.5B.
• The company reached a drug pricing deal with the U.S. government to lower prices in exchange for tariff exemptions, which is expected to impact 2026 revenue by hundreds of millions of dollars.
• A court-appointed special master recommended allowing expert testimony linking J&J's talc products to ovarian cancer, renewing legal pressures that have historically weighed on the stock price.
• The healthcare sector is facing operational pressure across England as norovirus cases rose 54% in a week, leading to nearly 1,000 hospital bed closures amid a winter cold snap.
• New research highlights a significant shift in the pharmaceutical market as ADHD medication usage has tripled over 13 years, with a notable 20-fold increase in prevalence among adult women.